Product Information

Fasiglifam is a biphenyl compound.

CAS No.	1000413-72-8
Product Name	Fasiglifam

Biological Targets

FFAR1

Associated Conditions

diabetes mellitus·type 2 diabetes mellitus

* The information provided here is compiled from public sources and is for reference only.

Studies related to this compound and its mechanism of action

Comparative hepatic transcriptome analyses revealed possible pathogenic mechanisms of fasiglifam (TAK-875)-induced acute liver injury in mice.

Chemico-biological interactions • Vol. 296 • 2018

PMID: 30243991 DOI: 10.1016/j.cbi.2018.09.011

Fasiglifam (TAK-875): Mechanistic Investigation and Retrospective Identification of Hazards for Drug Induced Liver Injury.

Toxicological sciences : an official journal of the Society of Toxicology • Vol. 163, Issue 2 • 2018

PMID: 28206647 DOI: 10.1093/toxsci/kfx040

Fasiglifam (TAK-875) Alters Bile Acid Homeostasis in Rats and Dogs: A Potential Cause of Drug Induced Liver Injury.

Toxicological sciences : an official journal of the Society of Toxicology • Vol. 157, Issue 1 • 2017

PMID: 28108665 PMC: PMC5414857 DOI: 10.1093/toxsci/kfx018

Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial.

Diabetes, obesity & metabolism • Vol. 17, Issue 7 • 2015

PMID: 25787200 PMC: PMC4676912 DOI: 10.1111/dom.12467

Fasiglifam

CAS No.	1000413-72-8
MDL No.	MFCD18251445
MF	C₂₉H₃₂O₇S
MW	524.60
InChI Key	BZCALJIHZVNMGJ-HSZRJFAPSA-N

CUSTOM SYNTHESIS PRECLINICAL SUPPORT

Pricing & Availability

Pack Size	Purity	Price	Availability	Action
-	-	On Request	On Request
Custom synthesis and bulk supply options are available upon request.

Product Information

Fasiglifam is a biphenyl compound.

CAS No.	1000413-72-8
Product Name	Fasiglifam

Biological Targets

FFAR1

Associated Conditions

diabetes mellitus·type 2 diabetes mellitus

* The information provided here is compiled from public sources and is for reference only.

Fasiglifam

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Fasiglifam

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Documentation

Fasiglifam

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Related Articles

Comparative hepatic transcriptome analyses revealed possible pathogenic mechanisms of fasiglifam (TAK-875)-induced acute liver injury in mice.

Fasiglifam (TAK-875): Mechanistic Investigation and Retrospective Identification of Hazards for Drug Induced Liver Injury.

Fasiglifam (TAK-875) Alters Bile Acid Homeostasis in Rats and Dogs: A Potential Cause of Drug Induced Liver Injury.

Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial.

Similar Products

Mk-8666

Fasiglifam

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Related Articles

Comparative hepatic transcriptome analyses revealed possible pathogenic mechanisms of fasiglifam (TAK-875)-induced acute liver injury in mice.

Fasiglifam (TAK-875): Mechanistic Investigation and Retrospective Identification of Hazards for Drug Induced Liver Injury.

Fasiglifam (TAK-875) Alters Bile Acid Homeostasis in Rats and Dogs: A Potential Cause of Drug Induced Liver Injury.

Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial.

Similar Products

Mk-8666

Documentation